01—Abstract
Summary
Summary of the 10-K filed February 20, 2025. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. reported a net loss of $543.3 milliona for 2024, compared with $653.3 million in 2023, as the company moved toward commercialization.
Its first commercial product, Attruby (acoramidis), was approved by the FDA on November 22, 2024 for adults with ATTR-CM, and launched in the U.S. The European Commission approved acoramidis as Beyonttra on February 10, 2025, and Bayer plans a European launch in the first half of 2025. Revenue rose to $221.9 millionb in 2024 from $9.3 million in 2023, driven mainly by $207.7 million of upfront license and services revenue under the Bayer and Kyowa Kirin agreements. Net product revenue from Attruby was only $2.9 million, and the company states it has not yet generated substantial product revenue.
The balance sheet carries significant leverage. Total consolidated indebtedness was $1.7 billionc at December 31, 2024, including convertible notes and a senior secured term loan. The company also received $500.0 million under a Funding Agreement that carries a royalty of 5% of global Attruby net sales, which may rise to 10% in 2027, subject to a $950.0 million cap.
Cash and cash equivalents were $681.1 milliond, and working capital was $566.3 million. The company states that cash and proceeds from Attruby revenue should fund operations for at least the next 12 months, and that the prior substantial doubt about going concern was resolved.
Pipeline catalysts for 2025 include Phase 3 PROPEL 3 for low-dose infigratinib in achondroplasia, which completed enrollment in January 2025; Phase 3 FORTIFY interim analysis of BBP-418 for LGMD2I, with topline data expected in the second half of 2025; and a Phase 3 encaleret trial in ADH1, with topline results expected in the second half of 2025. The company's accumulated deficit reached $3.1 billion at year-end 2024.
02—Key points
Key Highlights
- FDA approved Attruby (acoramidis) on November 22, 2024 for ATTR-CM; the company launched commercially in the U.S. and the EC approved Beyonttra in Europe on February 10, 2025.
- Revenue was $221.9 million in 2024 versus $9.3 million in 2023, but most of it was upfront license and services revenue from Bayer and Kyowa Kirin; Attruby net product revenue was $2.9 million.
- Net loss narrowed to $543.3 million in 2024 from $653.3 million in 2023; the accumulated deficit was $3.1 billion at December 31, 2024.
- Total consolidated indebtedness was $1.7 billion at December 31, 2024, including 2027 and 2029 convertible notes and a $450.0 million term loan.
- The $500.0 million Funding Agreement obligates the company to pay royalties of 5% of global Attruby net sales (up to 10% in 2027), capped at $950.0 million in cumulative payments.
- Cash and cash equivalents were $681.1 million at year-end 2024; management expects existing resources and Attruby proceeds to fund operations for at least 12 months.
- Three late-stage programs have Phase 3 readouts expected in 2025, including BBP-418 (FORTIFY interim analysis) and encaleret (ADH1), in the second half of 2025.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 20, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $221.90M$9.30M | +2285.3% |
| Cost of Revenue | $3.88M$2.45M | +58.5% |
| Gross Profit | $218.02M$6.86M | +3079.6% |
| R&D Expenses | $506.46M$455.71M | +11.1% |
| SG&A Expenses | $288.93M$150.59M | +91.9% |
| Operating Expenses | $814.88M$616.67M | +32.1% |
| Operating Income | -$592.97M-$607.37M | +2.4% |
| Interest Expense | $34.33M$34.23M | +0.3% |
| Net Income | -$535.76M-$643.20M | +16.7% |
| EPS (Basic) | $-2.88$-3.95 | +27.1% |
| EPS (Diluted) | $-2.88$-3.95 | +27.1% |
| Shares Outstanding (Basic) | 186.08M162.79M | +14.3% |
| Shares Outstanding (Diluted) | 186.08M162.79M | +14.3% |
05—Questions
Frequently Asked Questions
How much revenue did BridgeBio generate in 2024, and how much came from Attruby?
Total revenue, net was $221.9 million in 2024, up from $9.3 million in 2023. Of this, $207.7 million came from recognizing the upfront license fee and services revenue under the Bayer License Agreement and the KKC Agreement, and $9.9 million came from remaining services revenue under the Navire-BMS License Agreement. Net product revenue from the commercial sale of Attruby in the U.S. was $2.9 million.
What is the company's debt position and how does the Funding Agreement affect it?
As of December 31, 2024, total consolidated indebtedness was $1.7 billion, including $550.0 million of 2.50% 2027 Notes and $747.5 million of 2.25% 2029 Notes, plus a $450.0 million term loan under the Amended Financing Agreement. The Funding Agreement provided $500.0 million in gross proceeds in December 2024, recorded as a deferred royalty obligation with a carrying value of $479.1 million. The Purchasers receive 5% of global Attruby net sales, which may rise to 10% in 2027, until payments reach a $950.0 million cap or a buy-out occurs.
Does the company have enough cash to fund operations?
The company reported cash and cash equivalents of $681.1 million and working capital of $566.3 million at December 31, 2024. It states that these balances, together with proceeds from Attruby product revenue, are expected to be sufficient to fund operations for at least the next 12 months. The filing also notes that its operating plan may change, and that it may need to raise additional capital sooner than planned.
What are the key near-term clinical and regulatory catalysts?
The company expects Phase 3 results from three late-stage programs over the next year. Enrollment in the PROPEL 3 Phase 3 trial of low-dose infigratinib in achondroplasia was completed on January 13, 2025. Topline data from the FORTIFY interim analysis of BBP-418 for LGMD2I and topline results from the Phase 3 encaleret trial in ADH1 are both expected in the second half of 2025. Bayer is expected to launch Beyonttra in Europe in the first half of 2025.
What competition and market risks does Attruby face?
Attruby competes with Vyndaqel and Vyndamax (tafamidis), marketed by Pfizer, and with Alnylam's vutrisiran, which the company anticipates may be approved for ATTR-CM in March 2025. The company also notes that Attruby's commercial success depends on market acceptance, reimbursement, and a limited specialty pharmacy distribution network. The filing states that the product's list price in the U.S. is $18,759.12 for a 28-day supply, and that a significant share of patients rely on government programs for coverage.
06—Continue